Tests a Chinese diet plan for type 2 diabetes and fatty liver disease
Tests a Chinese medical nutrition diet in adults with type 2 diabetes and fatty liver.
Plain-language title generated from the registry record
Registry title: Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease
Key facts
- Where
- Changsha and Yichang, ChinaSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) to test a Chinese medical nutrition therapy (CMNT) diet with intermittent energy restriction.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- Type 2 diabetes together with NAFLD; BMI between 18.0 and 35.0 kg/m2
- Earlier treatment
- Weight stable for at least 3 months (gain or loss under 4 kg (9 lb)). Stable treatment for at least 3 months with 1-3 oral antidiabetic medications (with or without insulin), or no antidiabetic medication yet.
Main reasons for not taking part
- Food allergy reported by the person
- Alcohol abuse in the last 3 months
- Other liver diseases such as chronic hepatitis B and C or autoimmune hepatitis
- Pregnant or planning pregnancy during the study
- Heart failure, or acute heart or brain blood vessel event in the past 90 days
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05439226, who can take part
Where in China
- Hunan Shanshui physical examination centerChangsha, ChinaTaking people
- Jinheyuan Outpatient Department, National Sub-health Intervention Technology Achievement Application CenterChangsha, ChinaTaking people
- Physical Examination Center of Gezhouba central hospital of SinopharmYichang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- State Key Laboratory of Subhealth Intervention Technology
- Trial code
- NCT05439226
- Record updated
- 25 July 2025
- Original description
Type 2 diabetes (T2D) represents a serious public health problem. Patients with T2D and non-alcoholic fatty liver disease(NAFLD) demonstrate a poor metabolic profile and increase mortality compared with patients with only NAFLD or T2D. Nutritional intervention is the most basic treatment for T2D. Previous study showed that a Chinese medical nutrition therapy (CMNT) diet, which intermittent use of low-calorie medicinal food, has a glucose-lowering effect in T2D. This study aims to investigate the effect of a Chinese medical nutrition therapy (CMNT) diet accompanied by intermittent energy restriction on reducing liver fat and glycated hemoglobin (HbA1c) in patients with T2D and NAFLD.Read full original descriptionShow less
Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease
Type 2 diabetes (T2D) represents a serious public health problem. Patients with T2D and non-alcoholic fatty liver disease(NAFLD) demonstrate a poor metabolic profile and increase mortality compared with patients with only NAFLD or T2D. Nutritional intervention is the most basic treatment for T2D. Previous study showed that a Chinese medical nutrition therapy (CMNT) diet, which intermittent use of low-calorie medicinal food, has a glucose-lowering effect in T2D. This study aims to investigate the effect of a Chinese medical nutrition therapy (CMNT) diet accompanied by intermittent energy restriction on reducing liver fat and glycated hemoglobin (HbA1c) in patients with T2D and NAFLD.
Inclusion: Patients diagnosed with type 2 diabetes and NAFLD; Age between 18 and 75 years; BMI between 18.0 and 35.0 kg/m2; Weight stable for at least 3 months prior to the study (gain or loss < 4 kg); Stable treatment for at least 3 months with 1-3 oral antidiabetic medications (with or without insulin therapy), or not yet received antidiabetic medication prior to the beginning of the study; Able to give written informed consent.
Exclusion: Scheduled to be hospitalized for any surgical treatment during screening; Level 3 hypoglycemic events (at least 3 times) occurring within the 90 days prior to screening; Self-reported a food allergy; Other liver diseases such as chronic hepatitis B and C, autoimmune hepatitis, primary biliary cirrhosis, hemochromatosis, nodular regenerative hyperplasia and focal nodular hyperplasia; Hospitalization or emergency department visit for hyperglycemia, diabetic ketoacidosis, lactic acidosis, hyperosmolar nonketotic coma, or diabetes; History of cancer within the past 5 years; Acute coronary or cerebrovascular event in the past 90 days, or heart failure; Hemorrhagic or ischemic stroke within the last 6 months; Alcohol abuse in the last 3 months (alcohol intake greater than 20 g per day for women; Alcohol intake for men greater than 40 g per day); Pregnant or planning of pregnancy during the study; Inability, physically or mentally, to adhere the procedures required by the study protocol.